147 related articles for article (PubMed ID: 29223619)
1. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
[TBL] [Abstract][Full Text] [Related]
2. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N; Crettol S; d'Esposito F; Tattam B; Hibbs DE; Murray M
Br J Pharmacol; 2010 Nov; 161(5):1059-69. PubMed ID: 20977456
[TBL] [Abstract][Full Text] [Related]
3. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.
Khan MS; Barratt DT; Somogyi AA
Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459
[TBL] [Abstract][Full Text] [Related]
5. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
Wang X; Zhang X; Liu F; Wang M; Qin S
Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.
Gillani TB; Rawling T; Murray M
Chem Res Toxicol; 2015 Jan; 28(1):92-102. PubMed ID: 25489883
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite.
Nair PC; Gillani TB; Rawling T; Murray M
Chem Biol Interact; 2021 Apr; 338():109401. PubMed ID: 33556367
[TBL] [Abstract][Full Text] [Related]
9. Ontogeny and sorafenib metabolism.
Zimmerman EI; Roberts JL; Li L; Finkelstein D; Gibson A; Chaudhry AS; Schuetz EG; Rubnitz JE; Inaba H; Baker SD
Clin Cancer Res; 2012 Oct; 18(20):5788-95. PubMed ID: 22927483
[TBL] [Abstract][Full Text] [Related]
10. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Miners JO; Chau N; Rowland A; Burns K; McKinnon RA; Mackenzie PI; Tucker GT; Knights KM; Kichenadasse G
Biochem Pharmacol; 2017 Apr; 129():85-95. PubMed ID: 28065859
[TBL] [Abstract][Full Text] [Related]
12. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Br J Pharmacol; 2012 Apr; 165(8):2787-98. PubMed ID: 22014153
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.
Ghassabian S; Gillani TB; Rawling T; Crettol S; Nair PC; Murray M
AAPS J; 2019 Jan; 21(2):15. PubMed ID: 30627802
[TBL] [Abstract][Full Text] [Related]
14. Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Cui PH; Rawling T; Gillani TB; Bourget K; Wang XS; Zhou F; Murray M
Biochem Pharmacol; 2013 Aug; 86(3):419-27. PubMed ID: 23732299
[TBL] [Abstract][Full Text] [Related]
15. The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2.
Gu R; Hibbs DE; Ong JA; Edwards RJ; Murray M
Biochem Pharmacol; 2014 Mar; 88(2):245-52. PubMed ID: 24462920
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.
Kim KA; Chung J; Jung DH; Park JY
Eur J Clin Pharmacol; 2004 Oct; 60(8):575-81. PubMed ID: 15365656
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
19. In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.
Wattanachai N; Polasek TM; Heath TM; Uchaipichat V; Tassaneeyakul W; Tassaneeyakul W; Miners JO
Eur J Clin Pharmacol; 2011 Aug; 67(8):815-24. PubMed ID: 21305272
[TBL] [Abstract][Full Text] [Related]
20. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect.
Adiwidjaja J; Boddy AV; McLachlan AJ
Pharm Res; 2020 Jun; 37(7):128. PubMed ID: 32529309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
